- 50 Million cash on hand. Total $10 billion sales potential.
-CANCER VACCINE: AEZS-120 cancer vaccine similar to Dendreon’s provenge. Phase I to begin mid-to-end 2010
-PHASE 3 TRIALS: 4 Phase 3 cancer trials in 2010:
1) AEZS-130 (SolorelTM) Diagnostic Adult Growth Hormone Deficiency trial. Filing of U.S. NDA planned after study completed later this year. 2) Perifosine, Multiple myeloma Cancer. 3) Perifosine, Refractory Advanced Colorectal. 4) AEZS-108, Ovarian Cancer.
AEZS could initiate also Perifosine phase III for treatment of Kidney Cancer. That would make it FIVE phase III cancer trials.
-PENDING PHASE 2 RESULTS (JUNE ASCO MEETING): Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC) are to be Presented by Donald Richards.
PARTNERS: AEterna stated publicly they are looking for partners, news could come at any time.
AEZS pipeline: Perifosine (phase III/KERX partner) Multiple Myeloma Advanced Colorectal Cancer Kidney Cancer and Others AEZS-108 (phase II) Endometrial Cancer Ovarian Cancer Other Cancers AEZS-112 (phase I) Solid Tumor AEZS-120 *Tumor Vaccine (pre-clinical **hello DNDN) Prostate Cancer AEZS-129/131PI3K/ErkInhibitor (pre-clinical) Oncology Cetrotide® (Marketed by Merck Serono, Nippon Kayaku / Shionogi (Japan)) In VitroFertilization AEZS-130 (SolorelTM) - Phase III Diagnostic –Adult Growth Hormone Deficiency AEZS-130 (macimorelin) - Phase I Therapeutic AEZS-123Ghrelin Antagonist - Preclinical